Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye surgery showdown: UNITY VCS vs CONSTELLATION trial pulled

NCT ID NCT07054281

Knowledge-focused Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to compare two surgical systems, UNITY VCS and CONSTELLATION, for treating various eye conditions like macular holes and retinal detachment. It was designed for adults needing vitreoretinal surgery. However, the trial was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Requires surgery for a clinically documented posterior vitreoretinal medical condition. * Clear ocular media except for vitreous hemorrhage and floaters undergoing surgery. * Other protocol-specified inclusion criteria may apply. Key Exclusion Criteria: * Presence of clinically significant ocular or systemic diseases that may interfere with study outcomes or safety. * Diagnosis of glaucoma or suspected ocular hypertension. * Recent intraocular eye surgery, other than cataract surgery, resulting in retained lens materials in the posterior segment (within the past 3-months). * Other protocol-specified exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epiretinal membrane are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

macular holes preretinal fibrosis proliferative diabetic retinopathy retinal perforation rhegmatogenous retinal detachment Vitreous Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epiretinal membrane Macular hole Proliferative diabetic retinopathy Retained lens material in the posterior segment Rhegmatogenous retinal detachment Visually significant vitreous floater Vitreomacular traction Vitreous hemorrhage

Contacts and locations

Locations

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota, 57701, United States

  • Charles Retina Institute

    Germantown, Tennessee, 38138, United States

  • NYC Retina - Manhattan

    New York, New York, 10003, United States

  • Retina Associates of Orange County

    Laguna Hills, California, 92653, United States

  • Retina Macula Institute of Arizona

    Scottsdale, Arizona, 85255, United States

  • The Eye Institute of Utah

    Salt Lake City, Utah, 84107, United States

  • Vision Research Center Eye Associates of New Mexico

    Albuquerque, New Mexico, 87109, United States

  • Wolfe Eye Clinic

    West Des Moines, Iowa, 50266, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.